Scroll

imiquimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
immunomodulators, both stimulant/suppressive and stimulant	1429	99011-02-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: imiquimod aldara beselna zyclara	A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS. Molecular weight: 240.31 Formula: C14H16N4 CLOGP: 3.24 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 56.73 ALOGS: -2.99 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

imiquimod
aldara
beselna
zyclara

A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.

Molecular weight: 240.31
Formula: C14H16N4
CLOGP: 3.24
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 56.73
ALOGS: -2.99
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.60 mg/mL	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 3 of 3 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Feb. 27, 1997	FDA	MEDICIS
Sept. 18, 1998	EMA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site erythema	88.83	24.81	22	1876	4813	63482311
Erythema	77.71	24.81	54	1844	175697	63311427
Application site reaction	76.19	24.81	14	1884	736	63486388
Application site scab	57.06	24.81	9	1889	187	63486937
Application site ulcer	54.77	24.81	8	1890	97	63487027
Application site erosion	49.82	24.81	8	1890	187	63486937
Skin erosion	48.53	24.81	12	1886	2600	63484524
Off label use	45.85	24.81	76	1822	674386	62812738
Influenza like illness	45.47	24.81	27	1871	66797	63420327
Application site inflammation	44.30	24.81	8	1890	381	63486743

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vital capacity decreased	121.86	27.25	21	2072	371	34954467
Scab	106.18	27.25	29	2064	4625	34950213
Application site erythema	94.62	27.25	23	2070	2313	34952525
Application site reaction	87.19	27.25	16	2077	409	34954429
Forced expiratory volume decreased	77.91	27.25	21	2072	3182	34951656
Erythema	74.75	27.25	53	2040	88727	34866111
Application site ulcer	70.09	27.25	9	2084	14	34954824
Pulmonary function test decreased	68.77	27.25	21	2072	4954	34949884
Application site inflammation	63.56	27.25	10	2083	97	34954741
Influenza like illness	61.71	27.25	31	2062	27603	34927235

Showing 1 to 10 of 21 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site erythema	177.13	22.30	42	3552	5068	79735726
Application site reaction	139.42	22.30	25	3569	751	79740043
Erythema	136.21	22.30	98	3496	223192	79517602
Application site inflammation	110.09	22.30	19	3575	455	79740339
Scab	94.88	22.30	30	3564	10542	79730252
Application site ulcer	94.83	22.30	14	3580	117	79740677
Application site scab	80.30	22.30	13	3581	208	79740586
Application site erosion	70.07	22.30	12	3582	274	79740520
Influenza like illness	69.16	22.30	42	3552	71665	79669129
Application site oedema	68.12	22.30	10	3584	80	79740714

Showing 1 to 10 of 39 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	D06BB10	DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:36710	interferon inducers
FDA MoA	N0000000157	Interferon Inducers
FDA PE	N0000009267	Increased Cytokine Activity
FDA PE	N0000009269	Increased Cytokine Production
MeSH PA	D000276	Adjuvants, Immunologic
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007369	Interferon Inducers

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Verruca	indication	30285000
Actinic keratosis	indication	201101007	DOID:8866
Condyloma acuminatum	indication	240542006	DOID:11168
Superficial basal cell carcinoma	indication	403914000
Neoplasm of vulva	off-label use	126922007	DOID:1245
Sunburn	contraindication	23346002
Immunosuppression	contraindication	38013005
Autoimmune disease	contraindication	85828009
Photosensitivity	contraindication	90128006
Graft-versus-host disease	contraindication	234646005

Showing 1 to 10 of 10 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.12	Basic
pKa2	5.99	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2.5%	ZYCLARA	BAUSCH	N022483	July 15, 2011	RX	CREAM	TOPICAL	11318130	Dec. 11, 2029	TREATMENT OF ACTINIC KERATOSIS
2.5%	ZYCLARA	BAUSCH	N022483	July 15, 2011	RX	CREAM	TOPICAL	8222270	Dec. 11, 2029	TREATMENT OF ACTINIC KERATOSIS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	10238645	Aug. 18, 2029	TREATMENT OF GENITAL WARTS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	10238645	Aug. 18, 2029	TREATMENT OF PERIANAL WARTS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	8598196	Aug. 18, 2029	TREATMENT OF GENITAL WARTS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	8598196	Aug. 18, 2029	TREATMENT OF PERIANAL WARTS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	10238644	Dec. 11, 2029	TREATMENT OF ACTINIC KERATOSIS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	8236816	Dec. 11, 2029	TREATMENT OF ACTINIC KERATOSIS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	8299109	Dec. 11, 2029	TREATMENT OF ACTINIC KERATOSIS
3.75%	ZYCLARA	BAUSCH	N022483	March 25, 2010	RX	CREAM	TOPICAL	10918635	April 30, 2030	TREATMENT OF GENITAL WARTS

Showing 1 to 10 of 15 entries

Previous1 2Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Toll-like receptor 7	Membrane receptor	Q9NYK1	TLR7_HUMAN	AGONIST	EC50	4.97	CHEMBL	CHEMBL
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN		Ki	5.53	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.83	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	5.89	DRUG MATRIX
7,8-dihydro-8-oxoguanine triphosphatase	Enzyme	P36639	8ODP_HUMAN		IC50	6.19	CHEMBL

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
006479	NDDF
108939005	SNOMEDCT_US
171571	MMSL
171678	MMSL
187724	MMSL
215085	RXNORM
386941002	SNOMEDCT_US
4021044	VUID
4021044	VANDF
4872	MMSL

Showing 1 to 10 of 23 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Aldara	HUMAN PRESCRIPTION DRUG LABEL	1	99207-260	CREAM	50 mg	TOPICAL	NDA	28 sections
Aldara	HUMAN PRESCRIPTION DRUG LABEL	1	99207-260	CREAM	50 mg	TOPICAL	NDA	28 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3133	CREAM	37.50 mg	TOPICAL	NDA authorized generic	27 sections
imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	0168-0432	CREAM	50 mg	TOPICAL	ANDA	25 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	45802-368	CREAM	12.50 mg	TOPICAL	ANDA	25 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4145	CREAM	50 mg	TOPICAL	ANDA	28 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4174	CREAM	37.50 mg	TOPICAL	ANDA	28 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4174	CREAM	37.50 mg	TOPICAL	ANDA	28 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	52549-4145	CREAM	50 mg	TOPICAL	ANDA	27 sections
Imiquimod	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6179	CREAM	50 mg	TOPICAL	ANDA	25 sections

Showing 1 to 10 of 26 entries

Previous1 2 3Next